01/23/2020 09:31
(Act. 23.01.2020 09:31)
–
–
–
Marinomed shares are in demand among investors. In an accelerated bookbuilding that was completed on Wednesday evening, almost twice as many shares were sold as originally offered. The sales price was 95 euros per share, the total sales proceeds are around 10 million euros, as the biotech company announced on Thursday.
On Wednesday, the three Marinomed shareholders Acropora Beteiligungs GmbH, behind which Saudis stands, Vetwidi Research Holding and BVT Beteiligungsverwaltung and Treuhand GmbH offered up to 55,000 papers for sale. In the end, 105,000, almost twice as many, were sold – including the fully exercised 50,000 share increase option. Shares with a value of around 7.1 percent of Marinomed’s share capital thus changed hands. The settlement should take place on January 27th. After the share placement, Acropora still holds around 16.6 percent, Vetwidi 1.5 percent and BAT 1.4 percent in Marinomed, according to the biotech company.
–
The Marinomed shares listed in the Vienna prime market were suspended on Wednesday after the accelerated bookbuilding became known. Regular trading resumed on Thursday, but there is no first price yet.
–
– ,
